JP2025521082A5 - - Google Patents

Info

Publication number
JP2025521082A5
JP2025521082A5 JP2024566227A JP2024566227A JP2025521082A5 JP 2025521082 A5 JP2025521082 A5 JP 2025521082A5 JP 2024566227 A JP2024566227 A JP 2024566227A JP 2024566227 A JP2024566227 A JP 2024566227A JP 2025521082 A5 JP2025521082 A5 JP 2025521082A5
Authority
JP
Japan
Prior art keywords
amino acid
acid residue
seq
protein
protein according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024566227A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025521082A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/062652 external-priority patent/WO2023217988A1/en
Publication of JP2025521082A publication Critical patent/JP2025521082A/ja
Publication of JP2025521082A5 publication Critical patent/JP2025521082A5/ja
Pending legal-status Critical Current

Links

JP2024566227A 2022-05-12 2023-05-11 安定化融合前hmpv融合タンパク質 Pending JP2025521082A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22173131 2022-05-12
EP22173131.8 2022-05-12
PCT/EP2023/062652 WO2023217988A1 (en) 2022-05-12 2023-05-11 Stabilized pre-fusion hmpv fusion proteins

Publications (2)

Publication Number Publication Date
JP2025521082A JP2025521082A (ja) 2025-07-08
JP2025521082A5 true JP2025521082A5 (enExample) 2026-05-19

Family

ID=81653543

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024566227A Pending JP2025521082A (ja) 2022-05-12 2023-05-11 安定化融合前hmpv融合タンパク質

Country Status (16)

Country Link
EP (1) EP4522209A1 (enExample)
JP (1) JP2025521082A (enExample)
KR (1) KR20250010642A (enExample)
CN (1) CN119562826A (enExample)
AU (1) AU2023269241A1 (enExample)
CA (1) CA3253332A1 (enExample)
CL (1) CL2024003418A1 (enExample)
CO (1) CO2024015386A2 (enExample)
CR (1) CR20240493A (enExample)
DO (1) DOP2024000230A (enExample)
GE (1) GEAP202516650A (enExample)
IL (1) IL316911A (enExample)
JO (1) JOP20240256A1 (enExample)
MX (1) MX2024013959A (enExample)
PE (1) PE20251395A1 (enExample)
WO (1) WO2023217988A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026504862A (ja) 2023-01-18 2026-02-10 ファイザー・インク 呼吸器疾患に対するワクチン
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
WO2025144636A1 (en) * 2023-12-26 2025-07-03 The Scripps Research Institute ENGINEERED hMPV F PROTEIN IMMUNOGENS AND RELATED VACCINES
WO2025163460A2 (en) * 2024-01-30 2025-08-07 Pfizer Inc. Vaccines against respiratory diseases
WO2026018181A1 (en) 2024-07-17 2026-01-22 Pfizer Inc. Immunogenic compositions and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
PL215165B1 (pl) 2002-04-25 2013-10-31 Crucell Holland Bv Rekombinowany wektor adenowirusowy oraz sposób wytwarzania rekombinowanego wektora adenowirusowego
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
JP7382230B2 (ja) 2016-10-17 2023-11-16 ヤンセン ファーマシューティカルズ,インコーポレーテッド 組み換えウイルスレプリコン系及びその使用
BR112019011661A2 (pt) 2016-12-05 2020-01-07 Synthetic Genomics, Inc. Composições e métodos para aumentar expressão de gene
US12559544B2 (en) * 2019-05-21 2026-02-24 University Of Georgia Research Foundation, Inc. Antibodies that bind human metapneumovirus fusion protein and their use
CN116615235A (zh) * 2020-10-09 2023-08-18 得克萨斯州大学系统董事会 融合前稳定的hmpv f蛋白

Similar Documents

Publication Publication Date Title
US11229694B2 (en) Vaccine against RSV
JP2018171063A5 (enExample)
EP3998077B1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
JP4925540B2 (ja) 5−ヘリックスタンパク質
US11759514B2 (en) Stabilized pre-fusion RSV F proteins
GB2598494A (en) A subunit vaccine for treatment or prevention of a respiratory tract infection
JP4006021B2 (ja) ケモカインの生物学的活性の強化法
WO1997026359A1 (es) Sistema de expresion de antigenos heterologos como proteinas de fusion
CN101255197B (zh) 血清白蛋白与白介素1受体拮抗剂的融合蛋白及应用
JP2003529319A (ja) HIV−1gp41を標的化する広範に中和する抗体を誘発する方法
RU2018100181A (ru) Модифицированный белок интерлейкина-7 и способы его применения
CN103314010B (zh) h[Gly2]GLP-2的固相合成
CA2187083A1 (fr) Fragment peptidique de la proteine g du virus respiratoire syncytial, agent immunogene, composition pharmaceutique le contenant et procede de preparation
RU2003104524A (ru) Masp-2, комплемент-связывающий фермент и его применение
JP2023528207A5 (enExample)
CN116096736A (zh) 新型冠状病毒rbd融合蛋白
WO2021247675A9 (en) Coronavirus-binding agents and uses thereof
RU2008146920A (ru) Клещевой аллерген домашней пыли
CN107226842A (zh) 靶向pd-1的多肽及其应用
JPH08511542A (ja) コイル状−コイルステムループ鋳型
JP2025509352A5 (enExample)
WO1999062932A2 (en) INHIBITION OF VIRAL INFECTION AND SPREAD WITH VIRAL AND RhoA-DERIVED PEPTIDES
CN115197303B (zh) 一种s蛋白的受体结合结构域的突变体及其应用
HK40051815A (en) Vaccine against rsv comprising modified f polypeptide
NZ804057B2 (en) Compositions including sbi adjuvants and methods of use thereof